Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in South India

Rant Balasubramanian, S. Sivasubramanian, V.K. Vijayan, Rajeswari Ramachandran, M.S. Jawahar, C.N. Paramasivan, N. Selvakumar, P.R. Somasundaram
{"title":"Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in South India","authors":"Rant Balasubramanian,&nbsp;S. Sivasubramanian,&nbsp;V.K. Vijayan,&nbsp;Rajeswari Ramachandran,&nbsp;M.S. Jawahar,&nbsp;C.N. Paramasivan,&nbsp;N. Selvakumar,&nbsp;P.R. Somasundaram","doi":"10.1016/0041-3879(90)90037-9","DOIUrl":null,"url":null,"abstract":"<div><p>A controlled study of three short-course regimens was undertaken in South Indian patients with newly diagnosed, sputum-positive pulmonary tuberculosis. The patients were allocated at random to one of three regimens: a) Rifampicin, streptomycin, isoniazid and pyrazinamide daily for 3 months (R3); b) the same regimen as above but followed by streptomycin, isoniazid and pyrazinamide twice-weekly for a further period of 2 months (R5); c) the same as R5 but without rifampicin (Z5). A bacteriological relapse requiring treatment occurred by 5 years in 16.8% of 113 R3,5.2% of 97 R5, and 20.0% of 115 Z5 patients with organisms sensitive to streptomycin and isoniazid initially. The differences in the relapse rates between the R3 and R5 regimens and the R5 and Z5 regimens were statistically significant (p &lt; 0.01 for both). Considering patients with organisms initially resistant to streptomycin or isoniazid or both, 7 of 52 patients (4 R3, 2 R5,1 Z5) had a bacteriological relapse requiring retreatment.</p></div>","PeriodicalId":23472,"journal":{"name":"Tubercle","volume":"71 4","pages":"Pages 253-258"},"PeriodicalIF":0.0000,"publicationDate":"1990-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0041-3879(90)90037-9","citationCount":"41","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tubercle","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0041387990900379","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 41

Abstract

A controlled study of three short-course regimens was undertaken in South Indian patients with newly diagnosed, sputum-positive pulmonary tuberculosis. The patients were allocated at random to one of three regimens: a) Rifampicin, streptomycin, isoniazid and pyrazinamide daily for 3 months (R3); b) the same regimen as above but followed by streptomycin, isoniazid and pyrazinamide twice-weekly for a further period of 2 months (R5); c) the same as R5 but without rifampicin (Z5). A bacteriological relapse requiring treatment occurred by 5 years in 16.8% of 113 R3,5.2% of 97 R5, and 20.0% of 115 Z5 patients with organisms sensitive to streptomycin and isoniazid initially. The differences in the relapse rates between the R3 and R5 regimens and the R5 and Z5 regimens were statistically significant (p < 0.01 for both). Considering patients with organisms initially resistant to streptomycin or isoniazid or both, 7 of 52 patients (4 R3, 2 R5,1 Z5) had a bacteriological relapse requiring retreatment.

南印度治疗痰阳性肺结核的3个月和2个5个月方案的5年结果
在南印度新诊断的痰阳性肺结核患者中进行了三种短期治疗方案的对照研究。患者被随机分配到三种方案中的一种:a)每日利福平、链霉素、异烟肼和吡嗪酰胺,持续3个月(R3);b)与上述相同的方案,但随后每周两次使用链霉素、异烟肼和吡嗪酰胺,再持续2个月(R5);c)与R5相同,但不含利福平(Z5)。最初对链霉素和异烟肼敏感的113例R3患者中有16.8%、97例R5患者中有5.2%、115例Z5患者中有20.0%需要治疗的细菌学复发。R3和R5方案以及R5和Z5方案的复发率差异有统计学意义(p <两者均为0.01)。考虑到最初对链霉素或异烟肼或两者均耐药的患者,52例患者中有7例(4例R3, 2例R5,1例Z5)出现细菌学复发,需要重新治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信